Hold2-5 weeks
Entry$14.19Now$10.04PnL-29.25%
87%
confidence
Angle MRT-8102 still has multiple H2 2026 shots after ZEUS read-through pressure knocked GLUE into a washout.
GLUE’s reversal has a company-specific why-now: H2 2026 includes IND submissions for next-gen NEK7 and cyclin E1 degraders plus a GFORCE-1 Phase 1 readout for MRT-8102 [#2, #6]. The stock was hit by a negative ZEUS read-through, but program-specific updates indicate MRT-8102 studies continue and multiple Phase 2 starts remain planned in H2 2026 [#14, #24].
HOLD AI Status: GLUE sits deeply oversold with short-term momentum stabilizing while the primary trend remains down, keeping focus on H2 2026 program catalysts.
Bollinger %B at 0.25 places price near the lower band with bandwidth around 33%, and stochastics show %K at 6.2 in oversold territory, consistent with a washed-out tape after the sector read-through. Daily MACD histogram is slightly positive with MACD above signal, and weekly histogram is still negative but rising, which often precedes stabilization even while price remains about 8.7% below the 20-day EMA and under the 50-week SMA. That mix fits the thesis that MRT-8102 and follow-on degrader IND work in H2 2026 remain the company-specific why-now while the chart digests pressure.
Triangulation
Indicators as of Oct 15, 2026 12:15 PM PT
| Trend | CAUTION | EMA20<SMA50<SMA200 · ADX 40.5 very_strong · -9.6% vs EMA20 · close<EMA20 · -DI > +DI |
| Momentum | HOLD | RSI 29.9 · RSIw 33.4 · hist 0.05 · MACD>signal |
| Stochastics | HOLD | %K/6 · %D/14 · oversold |
| Bollinger | HOLD | %B 0.22 · lower band · BW 33.2% · ATR 6.7% |
| Weekly | WATCHING | RSIw 32.5 · RSI<RSI-SMA · hist -0.96 · hist rising · close<SMA50 |
| Price action | WATCHING | 20d 5% · 52w 5% · lower highs (3) |
| Volume | HOLD | 0.74x avg · OBV ↓ |
| Position | CAUTION | PnL -29.39% · peak +5.14% · dd -31.11% · 32d held |
